The U.S. Food and Drug Administration has approved a new medication called Itovebi for treating a specific type of advanced breast cancer. It's designed for adults with hormone receptor-positive, HER2-negative breast cancer that has spread or is locally advanced, and has a particular genetic change called PIK3CA mutation. This drug is taken by mouth once daily and is used in combination with two other cancer medications.
This approval is specifically for patients whose cancer has stopped responding to hormone therapy after previous treatment. Doctors will need to test for the PIK3CA genetic change before considering this treatment option. The FDA's decision means there's now another choice available for this group of patients who may have limited treatment alternatives.
It's important to understand that this approval doesn't mean Itovebi is right for everyone with breast cancer. The drug is specifically for a certain type of cancer with particular characteristics. Like all medications, Itovebi may have side effects, and doctors may need to adjust doses based on how patients respond.
If you or someone you know has breast cancer, the most important step is to talk with your healthcare team about all available options. They can help determine if this new treatment might be appropriate based on individual circumstances and test results.
